Blood Levels of Ammonia and Carnitine in Patients Treated with Valproic Acid: A Meta-analysis

다국어 초록 (Multilingual Abstract)

Objective: Long-term valproic acid (VPA) administration is associated with adverse metabolic effects, including hyperammonemia and hypocarnitinemia. However, the pathogeneses of these adverse events remain unclear, and not enough reviews have been performed. The aim of this study was to conduct a meta-analysis of studies examining blood levels of ammonia and carnitine in patients treated with VPA.
Methods: We conducted database searches (PubMed, Web of Science) to identify studies examining blood levels of ammonia and carnitine in patients treated with VPA. A meta-analysis was performed to conduct pre- and post-VPA treatment comparisons, cross-sectional comparisons between groups with and without VPA use, and estimations of the standardized correlations between blood levels of ammonia, carnitine, and VPA.
Results: According to the cross-sectional comparisons, the blood ammonia level in the VPA group was significantly higher than that in the non-VPA group. Compared to that in the non-VPA group, the blood carnitine level in the VPA group was significantly lower. In the meta-analysis of correlation coefficients, the blood VPA level was moderately correlated with blood ammonia and blood free carnitine levels in the random effects model. Furthermore, the blood ammonia level was moderately correlated with the blood free carnitine level.
Conclusion: Although the correlation between ammonia and free carnitine levels in blood was significant, the moderate strength of the correlation does not allow clinicians to infer free carnitine levels from the results of ammonia levels.
Clinicians should measure both blood ammonia and free carnitine levels, especially in patients receiving high dosages of VPA.

참고문헌 (Reference)

1 Zelnik N, "Vigabatrin, lamotrigine, topiramate and serum carnitine levels" 39 : 18-21, 2008

2 Paganini M, "Venous blood ammonia concentrations in adult epileptic patients are increased by treatment with valproic acid" 6 : 442-446, 1984

3 Williams CA, "Valproic acidinduced hyperammonemia in mentally retarded adults" 34 : 550-553, 1984

4 Komatsu M, "Valproate-associated hyperammonemia and DL-carnitine supplement" 33 : 81-87, 1987

5 Beghi E, "Valproate, carnitine metabolism, and biochemical indicators of liver function. Collaborative Group for the Study of Epilepsy" 31 : 346-352, 1990

6 Hirose S, "Valproate therapy does not deplete carnitine levels in otherwise healthy children" 101 : E9-, 1998

7 Foster DW, "The role of the carnitine system in human metabolism" 1033 : 1-16, 2004

8 Hamed SA, "The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate : relationship to blood carnitine status" 86 : 32-41, 2009

9 Patsalos PN, "The prevalence of valproic-acid-associated hyperammonaemia in patients with intractable epilepsy resident at the Chalfont centre for epilepsy" 6 : 228-232, 1993

10 Opala G, "The effect of valproic acid on plasma carnitine levels" 145 : 999-1001, 1991

11 Okumura A, "Serum carnitine levels of children with epilepsy : related factors including valproate" 41 : 516-521, 2019

12 Castro-Gago M, "Serum carnitine levels in epileptic children before and during treatment with valproic acid, carbamazepine, and phenobarbital" 13 : 546-549, 1998

13 Laub MC, "Serum carnitine during valproic acid therapy" 27 : 559-562, 1986

14 Castro-Gago M, "Serum biotinidase activity in children treated with valproic acid and carbamazepine" 25 : 32-35, 2010

15 Anil M, "Serum and muscle carnitine levels in epileptic children receiving sodium valproate" 24 : 80-86, 2009

16 Tseng YL, "Risk factors of hyperammonemia in patients with epilepsy under valproic acid therapy" 93 : e66-, 2014

17 Duman B, "Risk factors for valproic acid induced hyperammonemia and its association with cognitive functions" 59 : 67-72, 2019

18 Yamamoto Y, "Risk factors for hyperammonemia in pediatric patients with epilepsy" 54 : 983-989, 2013

19 Hug G, "Reduction of serum carnitine concentrations during anticonvulsant therapy with phenobarbital, valproic acid, phenytoin, and carbamazepine in children" 119 : 799-802, 1991

20 Hiraoka A, "Reduction in blood free carnitine levels in association with changes in sodium valproate(VPA)disposition in epileptic patients treated with VPA and other anti-epileptic drugs" 20 : 91-93, 1997

21 Zelnik N, "Reduced carnitine and antiepileptic drugs : cause relationship or co-existence?" 84 : 93-95, 1995

22 Knobloch K, "Preferred reporting items for systematic reviews and meta-analyses(PRISMA)statement and publication bias" 39 : 91-92, 2011

23 Goto S, "Potential relationships between transaminase abnormality and valproic acid clearance or serum carnitine concentrations in Japanese epileptic patients" 60 : 267-272, 2008

24 Laub MC, "Nutritional influence on serum ammonia in young patients receiving sodium valproate" 27 : 55-59, 1986

25 Aires CC, "New insights on the mechanisms of valproate-induced hyperammonemia : inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA" 55 : 426-434, 2011

26 Redden L, "Long-term safety of divalproex sodium extended-release in children and adolescents with bipolar I disorder" 19 : 83-89, 2009

27 Melegh B, "L-carnitine replacement therapy in chronic valproate treatment" 21 : 40-43, 1990

28 Kondo T, "Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?" 33 : 550-554, 1992

29 Farkas V, "Inhibition of carnitine biosynthesis by valproic acid in rats--the biochemical mechanism of inhibition" 52 : 1429-1433, 1996

30 Croux C, "Influence functions of the Spearman and Kendall correlation measures" 19 : 497-515, 2010

31 Morita J, "Hypocarnitinemia in the handicapped individuals who receive a polypharmacy of antiepileptic drugs" 17 : 203-205, 1986

32 Agarwal R, "Hyperammonemia and hepatic status during valproate therapy" 24 : 366-369, 2009

33 Ratnaike RN, "Hyperammonaemia and hepatotoxicity during chronic valproate therapy : enhancement by combination with other antiepileptic drugs" 22 : 100-103, 1986

34 Balduzzi S, "How to perform a meta-analysis with R : a practical tutorial" 22 : 153-160, 2019

35 Farrell K, "Free and total serum valproate concentrations : their relationship to seizure control, liver enzymes and plasma ammonia in children" 13 : 252-255, 1986

36 Matsumoto K, "Fluorometric determination of carnitine in serum with immobilized carnitine dehydrogenase and diaphorase" 36 : 2072-2076, 1990

37 Nakajima Y, "Evaluation of valproate effects on acylcarnitine in epileptic children by LC-MS/MS" 33 : 816-823, 2011

38 Werner T, "Effects of valproate on acylcarnitines in children with epilepsy using ESI-MS/MS" 48 : 72-76, 2007

39 Melegh B, "Effect of chronic valproic acid treatment on plasma and urine carnitine levels in children : decreased urinary excretion" 28 : 137-142, 1987

40 Abbasnezhad A, "Effect of L-carnitine on liver enzymes and biochemical factors in hepatic encephalopathy : a systematic review and meta-analysis" 34 : 2062-2070, 2019

41 Haidukewych D, "Chronic valproic acid therapy and incidence of increases in venous plasma ammonia" 7 : 290-294, 1985

42 Engel AG, "Carnitine metabolism and inborn errors" 7 (7): 38-43, 1984

43 Moreno FA, "Carnitine levels in valproic acid-treated psychiatric patients : a cross-sectional study" 66 : 555-558, 2005

44 Riva R, "Carnitine disposition before and during valproate therapy in patients with epilepsy" 34 : 184-187, 1993

45 Qiliang L, "Carnitine deficiency in Chinese children with epilepsy on valproate monotherapy" 55 : 222-224, 2018

46 Van Wouwe JP, "Carnitine deficiency during valproic acid treatment" 65 : 211-214, 1995

47 Rodriguez-Segade S, "Carnitine deficiency associated with anticonvulsant therapy" 181 : 175-181, 1989

48 Verrotti A, "Carnitine deficiency and hyperammonemia in children receiving valproic acid with and without other anticonvulsant drugs" 29 : 36-40, 1999

49 Ohtani Y, "Carnitine deficiency and hyperammonemia associated with valproic acid therapy" 101 : 782-785, 1982

50 Maldonado C, "Carnitine and/or acetylcarnitine deficiency as a cause of higher levels of ammonia" 2016 : 2920108-, 2016

51 Verbiest HB, "Carbamyl phosphate synthetase-1 deficiency discovered after valproic acid-induced coma" 86 : 275-279, 1992

52 Sharma S, "Blood ammonia levels in epileptic children on 2 dose ranges of valproic acid monotherapy : a cross-sectional study" 26 : 109-112, 2011

53 Kugoh T, "Blood ammonia level during valproic acid therapy" 40 : 663-668, 1986

54 Monti B, "Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection" 2 : 95-109, 2009

55 Altunbaşak S, "Asymptomatic hyperammonemia in children treated with valproic acid" 12 : 461-463, 1997

56 Yokoyama S, "Association between the serum carnitine level and ammonia and valproic acid levels in patients with bipolar disorder" 42 : 766-770, 2020

57 Ando M, "Association between the blood concentrations of ammonia and carnitine/amino acid of schizophrenic patients treated with valproic acid" 11 : 19-, 2017

58 Günaydın YK, "Antiepileptic drug poisoning : three-year experience" 2 : 56-62, 2014

59 Cansu A, "Analysis of acylcarnitine levels by tandem mass spectrometry in epileptic children receiving valproate and oxcarbazepine" 13 : 394-400, 2011

60 Thom H, "Ammonia and carnitine concentrations in children treated with sodium valproate compared with other anticonvulsant drugs" 33 : 795-802, 1991